Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Valtropin Is The Second Biosimilar Product Approved In Europe

This article was originally published in The Pink Sheet Daily

Executive Summary

Biopartners’ somatropin is a follow-on to Pfizer’s Genotropin.

You may also be interested in...



EMEA Denies Biosimilar To Roche’s Interferon Alfa-2a

BioPartners’ Alpheon – a generic version of Roferon-A – has “major quality concerns,” the European Medicines Agency finds.

EMEA Denies Biosimilar To Roche’s Interferon Alfa-2a

BioPartners’ Alpheon – a generic version of Roferon-A – has “major quality concerns,” the European Medicines Agency finds.

Omnitrope Gains Final EU Approval

Sandoz will launch the Genotropin follow-on in Germany and Austria in the coming days.

Related Content

Topics

UsernamePublicRestriction

Register

PS064268

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel